Kinito (Itopride Hydrochloride)

Itopride Hydrochloride works by blocking peripheral dopamine D2 receptors, which reduces inhibitory dopaminergic signals on the gut. At the same time, it inhibits acetylcholinesterase, increasing acetylcholine levels and stimulating smooth‑muscle contraction, thereby enhancing gastric emptying and overall gastrointestinal motility.

The dosage of Kinito is determined by the prescribing clinician based on the individual’s condition, age, and response to therapy. The prescriber will select the appropriate strength, frequency, and duration according to current clinical guidelines and patient needs.

Safety data for Itopride Hydrochloride in pregnancy and lactation are limited. The product should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and it should be prescribed after a careful risk‑benefit assessment.

To request Kinito, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Kinito (Itopride) differs from agents such as domperidone or metoclopramide by combining dopamine D2 antagonism with acetylcholinesterase inhibition, which may provide a broader pro‑motility effect. It generally has a lower risk of central nervous system side effects compared with metoclopramide, while offering comparable efficacy in functional dyspepsia.

Kinito tablets should be stored at ambient temperature, below 25 °C. Keep them in the original blister pack or container, protect from moisture and direct sunlight, and ensure they are out of reach of children.

Kinito is taken orally, usually with a glass of water. The prescribing physician may advise taking the tablet before meals to maximise its pro‑kinetic effect, but the exact timing should follow the clinician’s instructions.

Serious but rare risks include severe allergic reactions (rash, swelling, breathing difficulty), cardiac arrhythmias, and significant hepatic dysfunction. Patients should seek immediate medical attention if they experience symptoms such as persistent vomiting, unexplained bruising, or signs of an allergic response.

Kinito is contraindicated in individuals with known hypersensitivity to itopride or any tablet excipients, in patients with severe hepatic impairment, and in those taking medications that may cause dangerous QT prolongation. It should also be avoided in patients with uncontrolled cardiac arrhythmias.